Evidence map›Paper›PMID 15573910›Full record

ArticleDigestive diseases and sciences2004

Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.

Yao Hong Wei, Li Jun, Chen Ji Qiang

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Losartan modifies mesh integration after abdominal wall repair: an experimental study.Hernia : the journal of hernias and abdominal wall surgery · 2022
    Article
  6. Review
  7. Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.Liver international : official journal of the International Association for the Study of the Liver · 2009
    Article
  14. ANG II-AT1 receptor pathway is involved in the anti-fibrotic effect of beta-elemene.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2009
    Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yao Hong WeiDepartment of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310031, China. yhgwei@hotmail.com
Li Jun
Chen Ji Qiang
Zhejiang University · CNAnhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to regulating blood pressure and body fluid homeostasis, the renin-angiotensin system (RAS) is also involved in hepatic fibrogenesis. We aimed to investigate the effect of losartan, an angiotensin II (Ang II) antagonist, on CCl4-induced hepatic fibrosis in rats. Hepatic fibrosis was induced by a subcutaneous injection with 50% CCl4 in Sprague-Dawley rats. The amount of CCl4 administered was 1 mg/kg. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in plasma and hydroxyproline (Hyp) contents in liver tissue were assayed by spectrophotometry. Hyaluronic acid (HA) and procollagen III (PC III) were assessed by radioimmunoassay. Tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta1 (TGF-beta1) levels in culture supernatants of Kupffer cells (KCs) stimulated with Ang II was determined by ELISA. Liver samples collected after 12 weeks of CCl4 treatment were stained with hematoxylin and eosin, then scored. Losartan (2.5, 5, and 10 mg x kg(-1), ig) and captopril (100 mg x kg(-1), ig) significantly decreased liver and spleen indexes, serum transaminase (AST, ALT) activities, HA and PC III levels, and Hyp contents in liver tissue in rats of hepatic fibrosis. Histopathological scores showed that losartan had an inhibitory effect on the progression of hepatic fibrosis. In in vitro experiments, losartan (1 x 10(-9) - 1 x 10(-5) M) significantly reduced TNF-alpha and TGF-beta1 levels in culture supernatants of KCs, but captopril (1 x 10(-5) M) did not. The results showed that losartan significantly inhibited the progression of hepatic fibrosis induced by CCl4, and the inhibitory effect of losartan on hepatic fibrosis might be associated with its ability to inhibit the production of TNF-alpha and TGF-beta1 by activated KCs.

Indexed as

Alanine TransaminaseAngiotensin II Type 1 Receptor BlockersAnimalsAspartate AminotransferasesCarbon TetrachlorideLiver CirrhosisLosartanMaleRatsRats, Sprague-DawleyTransforming Growth Factor betaTransforming Growth Factor beta1Tumor Necrosis Factor-alphaAlanine TransaminaseAngiotensin II Type 1 Receptor BlockersAspartate AminotransferasesCarbon TetrachlorideLosartanTgfb1 protein, ratTransforming Growth Factor betaTransforming Growth Factor beta1Tumor Necrosis Factor-alpha

Identifiers

PMID15573910
OpenAlexW2097000993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.